This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synthetic Biologics To Present At OneMedForum San Francisco 2013

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that Jeffrey Riley, CEO, will present at the Sixth Annual OneMedForum San Francisco 2013 on Wednesday, January 9, 2013 at 9:20 a.m. (PT)/ 12:20 p.m. (ET). The conference will be held January 7-9, 2013 at the Sir Francis Drake Hotel in San Francisco, California.

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://onemedplace.com/forum/webcast/. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on Synthetic Biologics' website at www.syntheticbiologics.com for 30 days following the conference.

A bout Synthetic Biologics, Inc.

Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. diff infection, and a series of monoclonal antibodies for the treatment of serious infectious diseases, including pertussis and Acinetobacter. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and is designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.



SOURCE Synthetic Biologics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.79 +32.82 0.18%
S&P 500 2,105.45 -3.47 -0.16%
NASDAQ 5,045.7280 -14.5180 -0.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs